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Abstract: Electrospinning is a flexible polymer processing method to produce nanofibres, which
can be applied in the biomedical field. The current study aims to develop new electrospun hybrid
nanocomposite systems to benefit the sustained release of hydrophilic drugs with hydrophobic
polymers. In particular, electrospun hybrid materials consisting of polylactic acid (PLA):poly(ε-
caprolactone) (PCL) blends, as well as PLA:PCL/halloysite nanotubes-3-aminopropyltriethoxysilane
(HNT-ASP) nanocomposites were developed in order to achieve sustained release of hydrophilic
drug tetracycline hydrochloride (TCH) using hydrophobic PLA:PCL nanocomposite membranes
as a drug carrier. The impact of interaction between two commonly used drugs, namely TCH and
indomethacin (IMC) and PLA:PCL blends on the drug release was examined. The drug release
kinetics by fitting the experimental release data with five mathematical models for drug delivery
were clearly demonstrated. The average nanofiber diameters were found to be significantly reduced
when increasing the TCH concentration due to increasing solution electrical conductivity in contrast
to the presence of IMC. The addition of both TCH and IMC drugs to PLA:PCL blends reduced the
crystallinity level, glass transition temperature (Tg) and melting temperature (Tm) of PCL within the
blends. The decrease in drug release and the impairment elimination for the interaction between
polymer blends and drugs was accomplished by mobilising TCH into HNT-ASP for their embedding
effect into PLA:PCL nanofibres. The typical characteristic was clearly identified with excellent
agreement between our experimental data obtained and Ritger–Peppas model and Zeng model in
drug release kinetics. The biodegradation behaviour of nanofibre membranes indicated the effective
incorporation of TCH onto HNT-ASP.
Keywords: electrospun nanofibres; nanocomposites; polylactic acid (PLA); poly(ε-caprolactone)
(PCL); halloysite nanotubes (HNTs); drug release; release kinetic modelling
1. Introduction
Electrospinning, as a combination of two processing methods, namely electrospraying
and spinning [1,2], is an efficient, convenient and versatile method for creating reliable ultra-
fine fibres from polymer solutions. It has been a hot subject with significant growing interest
to scientific communities during recent years. It offers a promising technique to manufac-
ture continuous fibres with the diameters ranging from nanometres to microns [3,4]. It
is also deemed as an alternative approach to fabricate hybrid fibre membranes based on
polymer nanocomposites when compared with commonly used manufacturing processes
of twin-screw extrusion, high shear mixing and injection moulding. Polymer nanocom-
posites when incorporated with nanoparticles become very attractive advanced materials
due to their well-tailored properties [5] and unique structures, which might not be possibly
accomplished in conventional composites [6,7]. Halloysite nanotubes (HNTs) have also
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gained widespread attention as tubular clay-based nanoparticles with cost-effectiveness
mainly used for the reinforcement purpose [8]. In general, poly(ε-caprolactone) (PCL) is a
hydrophobic and semi-crystalline polymer [9]. It degrades in the body due to the existence
of an aliphatic ester bond for hydrolysis [10], and the resulting materials can be metabolised
via tricarboxylic acid cycle or eliminated directly by the renal secretion [11]. On the other
hand, polylactic acid (PLA), as one of the most promising biodegradable polymers, has
remarkable material merits including easy processability, ability to be dissolved in common
solvents, good sustainability and reasonable biocompatibility [12,13]. Since PLA has a low
degree of crystallinity, when compared with PCL, which can degrade to form nontoxic
monomers, it is well utilised in biomedical applications such as medical devices, drug
delivery, tissue scaffolding, etc. [14]. As a typical example, it submits the secession to
monomeric units of lactic acid in the body, which naturally takes place in the carbohydrate
metabolism [15,16]. Whereas, PCL is a slowly degraded biopolymer as opposed to many
other counterparts such as PLA owing to its semi-crystalline nature [17,18] and a high
degree of crystallinity. Moreover, PCL is not harmful to local tissues because it does not
form an acidic environment like poly(lactide-co-glycolide) (PLGA) or PLA. In the past
decades, the use of polymers, as a carrier and release controller for drug delivery systems,
has been the major research focus due to the improvement of healing effectiveness and
the reduction in toxic side-effect [19]. In addition, the interaction between drugs and their
carriers is paramount to control a sustained drug release [20,21]. Hydrophobic drugs
including clindamycin, ciprofloxacin, and cephalexin can be simply incorporated with,
and thus interacted with hydrophobic polymers. However, hydrophilic drugs cannot be
embedded into hydrophobic polymers due to their weak interactions while the drug release
rate may not be well controlled [22]. This study aims to develop new electrospun hybrid
nanocomposite systems to benefit the sustained release of hydrophilic drugs when encoun-
tered with hydrophobic polymers in order to ultimately overcome the weak interaction
issue identified between the drugs and their carriers.
2. Materials and Methods
2.1. Materials
PLA 3051D (molecular weight (MW) = 93,500 g/mol) was supplied by Nature Works,
Blair, Nebraska, USA. PCL (MW = 80,000 g/mol), tetracycline hydrochloride (TCH)
(C22H24N2O8·HCl, MW= 480.9 g/mol) shown in Figure 1a, Indomethacin (IMC)
(C19H16ClNO4, MW = 357.79 g/mol) illustrated in Figure 1b, phosphate buffer solution
(PBS), chloroform and methanol were all purchased from Sigma-Aldrich Ltd., Castle Hill,
NSW, Australia, and these materials were used without any purification. Halloysite nan-
otubes (HNT) were obtained from Imerys Ceramics, Kaeo, Northland, New Zealand.
2.2. Electrospinning
TCH and IMC drugs with a fixed concentration of 5 wt% were initially mixed with
blend solutions (i.e., PLA:PCL at a mix ratio of 1:1), in which TCH was mixed with
1wt%/v HNT-ASP and subsequently added to PLA:PCL solution. The solvent used
in all cases was the mixture of chloroform and methanol (volume ratio: 2:1). In the
following electrospinning process, different types of solutions were transferred to a 10 mL
syringe pump (A Fusion 100 syringe pump, Chemyx Inc., Stafford, TX, USA) with a needle
specification of 20 G (inner diameter: 0.584 mm). The flow rate of the solution was set
to 2 mL/h, the applied voltage was in the range of 25–28 kV, and the needle-to-collector
distance was fixed at 13 cm. The electrospinning process was carried out at 24 ◦C in the
closed system and in ventilated fume cupboards with optimal conditions of humidity and
temperature. The polymer solution was electrospun immediately after being prepared
to reduce the effect of environmental conditions. The resulting fibres were collected on a
ground collector covered by flat aluminium foil. A sharp blade was used to cut fibre mats
and they were removed with fine forceps. The thicknesses of fibre mats produced were
measured using a digital electronic micrometer, recorded in the range from 330 to 450 µm.
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Figure 1. Chemical structure of two model drugs: (a) TCH [23] and (b) IMC [24].
2.3. In Vitro Drug Release Study
The drug-loaded fibre mat samples (sample size: 2 cm × 2 cm) were incubated in
20 mL PBS (pH = 7.4) using a rotary shaker at 37 ◦C. After the required incubation time
for drug release, the samples were transferred to 20 mL fresh buffer solution and 36
separate incubations were conducted to obtain TCH and IMC release data for the three
nanofibre mats (i.e., PLA:PCL/IMC, PLA:PCL/TCH and PLA:PCL/HNT-ASP/TCH) and
subsequently, the released drug amount in the buffer solution was determined accordingly.
The percentage of the released drug was calculated from the primary weight of the
drug (i.e., TCH and IMC) contained in the electrospun mats. The cumulative amount of
drug released from nanofibre mats was calculated according to the following Equation:






where Mt is the number of drugs released up to time t and M∞ is the initial amount of drug
within electrospun fibres.
2.4. Mathematical Models for Drug Release Kinetics
The kinetics of TCH and IMC release from nanofibre mats were determined from the
release curves against time t. The experimental drug release data were fitted to five typical
mathematical models for drug release kinetics consisting of conventional zero-order model,
first-order model, Higuchi model, Ritger–Peppas model, as well as Zeng model [20].
2.4.1. Zero-Order Model
A zero-order model is employed to a drug delivery system in which the drug release
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where Mt, M∞ and K0 are the absolute cumulative amounts by mass of drug released at
time t and infinite time, and zero-order release constant, respectively. The ratio Mt/M∞
denotes the cumulative amount released in percentage [26].
2.4.2. First-Order Model
The first-order equation can be expressed in a derived mathematical form [27] for the
released drug in an aqueous phase [28] given below
Mt
M∞
= 1 − eK1t (3)
in which K1 is the first-order release constant.
2.4.3. Higuchi Model
Higuchi [29] developed important mathematical models to study the release of water-







where KH is Higuchi kinetic constant that reflects design variables in a drug delivery
system.
2.4.4. Ritger–Peppas Model
Ritger and Peppas [25] established a simple exponential relationship to investigate
both Fickian and non-Fickian drug release conditions in swelling and non-swelling poly-




where KR is Ritger–Peppas kinetic constant, which incorporates structural and geometric
characteristics of a macromolecular network system and the drug. n is the diffusion
exponent for the transport mechanism through the polymer.
2.4.5. Zeng Model
Zeng and co-workers [20] developed a three-parameter model with the close-form
analytical solution to consider the reversible drug–carrier interaction and first-order drug
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In Equation (6), Kon is the rate constant of association for non-dispersed drug molecules
in the system to be disassociated from carriers prior to drug release. Conversely, Koff is
the rate constant of disassociation accordingly and KS is a constant proportional to the
surface-to-volume ratio of the carriers in order to improve drug release. In addition, ∆G
is the difference of free energy between the free and bound states, kB is the Boltzmann’s
constant and T is the absolute temperature where T = 300 K in Equation (7). Koff, KS and ∆G
are three critical parameters in Zeng model to explain the effect of cumulative drug release.
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2.5. In Vitro Biodegradation Study
With respect to in vitro degradation studies, nanofibre mats with the thickness ranging
from 300 to 450 µm were cut into 2 cm × 2 cm testing samples. They were measured to
determine the initial weight (m) and then were placed into an incubated rotary shaker at
the rotor speed of 100 rpm and the temperature of 37 ◦C during the biodegradation study
where 15 mL PBS (pH = 7.4) was utilised for the required incubation time.
Such nanofibre mats were removed at each designated incubation period and washed
with deionised water. These mats were dried under vacuum at 37 ◦C until they reached a
constant weight (m1). Mass loss (%) was determined using the equation below







The morphology of electrospun nanofibres was examined via an EVO 40XVP scanning
electron microscope (SEM) (Carl Zeiss AG, Jena, Germany) at the accelerating voltage
of 5 kV. Before SEM observation, the samples were sputter-coated with platinum. Fibre
diameters were calculated from the SEM images by using an image analysis tool within
Zeiss Smart SEM software. A minimum of 150 fibres was selected from multiple scanned
SEM images for the measurements per sample based on a sampling rate of 15 fibres
per image.
Solution viscosity was determined with the aid of a Visco 88 portable viscometer from
Malvern Instruments, Malvern, UK. The electrical conductivity of the solution was mea-
sured by using a WP-81 Waterproof Conductivity Meter, TPS, Brendale, QLD, Australia).
XRD measurements of prepared samples were undertaken in a Bruker Discover 8
X-ray diffractometer, Bruker Corporation, Berlin, Germany. It operated at 40 kV and
40 mA using Cu-Kα radiation subjected to the monochromatisation with graphite sample
monochromators in a 2θ range from 5◦ to 40◦ (scanning rate: 0.05◦/s).
Thermal analysis was performed via a DSC6000 Perkin Elmer, Boston, MA, USA with
a cryofill liquid nitrogen cooling system. Approximately 10 mg fibre mat was cut and
sealed in an aluminium pan. The thermal behaviour was analysed during the first heating
scan in a temperature range from −90 ◦C to 200 ◦C at the ramp rate of 10 ◦C/min.
Thermogravimetric analysis (TGA) was carried out by using a SeikoSII Exstar 6000
(TG/DTA 6200), Tokyo, Japan to evaluate the thermal decomposition effect of electrospun
PLA:PCL fibres loaded with drugs. About 6–10 mg TGA samples were heated from 40 ◦C
to 900 ◦C at a heating ramp rate of 10 ◦C/min under a nitrogen flow of 200 mL/min [30].
Fourier transform infrared spectroscopy (FTIR) was performed in a Spectrum 100
FTIR Spectrometer, Perkin Elmer, Kanagawa, Japan. Resulting spectra were recorded in a
wavenumber range of 4000–550 cm−1 with the resolution of 4 cm−1 by using an attenuated
total reflectance (ATR) technique [31].
The amount of TCH present in the release PBS was obtained by means of a UV-vis
spectrophotometer, JascoV-67, Easton, MD, USA at two specific wavelengths of 360 nm [32]
and 319 nm [33] for TCH and IMC drugs accordingly.
4. Results and Discussion
4.1. Drug Effect on Fiber Morphology
To investigate the drug effect, PLA:PCL polymer solution was blended with IMC and
TCH at a fixed concentration of 5 wt%. As observed in Figures 2 and 3, loaded IMC gave
rise to uniform composite fibrous structures in possession of much larger fibre diameters
at approximately 794 nm as opposed to 623 nm for TCH counterparts. No remarkable
variation in fibre diameter was identified with the addition of IMC when compared with
PLA:PCL blend fibres. Similarly, PLA:PCL/HNT-ASP/TCH composites were also found
to attain uniform fibrous structures despite a small fibre diameter of 716 nm relative to
those PLA:PCL blends and PLA:PCL/HNT-ASP composites.
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Figure 2. Scanning electron micrographs of electrospun fibre mats (a) PLA:PCL (b) PLA:PCL/HNT-ASP (c) PLA:PCL/IMC
(d) PLA:PCL/TCH and (e) PLA:PCL/HNT-ASP /TCH. All the scale bars represent 10 µm in size.
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 Corrected Figure 3 
Figure 3. Effects of HNT-ASP, IMC and TCH on nanofibre diameter.
Figure 4 reveals that the addition of IMC to PLA:PCL solution did not appear to
significantly affect the solution electrical conductivity in good accordance with previous
work [34]. However, as expected, the use of cationic drug TCH further increases the solution
conductivity. The additional amphoteric molecules of TCH, having several ionisable
functional groups [35], further increases the solution conductivity as compared to that
without TCH.
Figure 4. Effects of HNT-ASP, IMC and TCH on solution electrical conductivity.
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4.2. Crystallinity Level
An XRD examination was carried out to investigate the impact of drug type on
crystallinity level and fibrous structures of electrospun nanocomposites fibre mats. The as-
sociated crystalline peaks in XRD patterns were directly detected with the aid of a DICVOL
program used in the FullProf software [36] and labelled with XRD reflection and crystal
planes (hkl) accordingly. Figure 5 illustrates the XRD patterns with respect to fibre mats of
PLA:PCL, PLA:PCL/TCH, PLA:PCL/IMC and PLA:PCL/HNT-ASP/TCH. Such patterns
possess two distinct diffraction peaks at the angles of 2θ = 20.1◦ and 23.2◦ corresponding
to the crystal planes (101) and (200), respectively. In particular, the characteristic XRD
peak of PCL/HNT-ASP/TCH was detected at 2θ = 12.4◦, which is indicative of the HNT
reflection plane (001). The basal reflection of HNTs results from their tubular morphological
structures and small crystal size L = 21.7 nm obtained according to the Scherrer relation [8].
No significant difference in relation to peak position was manifested regardless of different
material samples, indicating the minor effect arising from loaded TCH and IMC to alter
crystalline structures of electrospun nanocomposite fibre mats. As such, it may be revealed
that TCH and IMC are most likely to be dispersed in an amorphous state into PLA:PCL
fibre mats. This may be attributed to rapid solvent evaporation, which did not have enough
time to cause relaxation of chain orientation. A short period for drug recrystallisation
and the formation of a preferred configuration in the amorphous state would take place
accordingly [37].
Figure 5. XRD patterns for selected material samples showing the relative positions of reflection
peaks when loaded with TCH and IMC drugs.
Figure 6 suggests that the degree of crystallinity (Xc) of nanocomposite fibre mats
is reduced more remarkably when TCH is concurrently added, as opposed to that of
PLA: PCL counterparts. Additionally, the use of IMC loaded to PLA:PCL fibre mats was
found to influence Xc more significantly in comparison with TCH loaded counterparts.
It is evidently shown that the presence of TCH and IMC enables to greatly accelerate
the nucleation effect, thus resulting in a shorter period than the required time for the
disentanglement of molecular chains. This is because the resulting degree of crystallinity
can be impacted by the restricted mobility of polymeric chains in order to prevent the more
rapid growth of developed crystals. In addition, the crystallinity of nanocomposites was
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reduced when HNT-ASP was embedded into polymers due to the diminished mobility of
polymeric chains.
Figure 6. Degree of crystallinity (Xc) of electrospun PLA: PCL fibre mats loaded with TCH and IMC drugs.
4.3. Thermal Properties
The thermal properties of electrospun nanocomposite fibre mats loaded with IMC
and TCH separately via differential scanning calorimetry (DSC) are shown in Table 1
and Figure 7. There is a considerable decreasing trend with respect to the Tg of PCL
within nanocomposite fibre mats despite a slight decline for the Tm levels of both PLA and
PCL when embedded with HNT-ASP and drug-loaded with 5 wt%/v TCH. The effect of
decreased Tg can be associated with the low molecular weight of TCH. Short molecular
chains of TCH are believed to yield the decline in the packing density of polymeric chains,
thus facilitating the chain mobility as a result of lower Tg. On the contrary, the addition of
TCH offers a significant increase in Tc with respect to electrospun nanocomposites.
Table 1. Thermal properties of PLA:PCL fibre mats and PLA:PCL nanocomposite fibre mats loaded
with TCH and IMC.









PLA:PCL −52.19 63.75 83.97 152.54 58.84
PLA:PCL/IMC −58.55 54.57 82.01 148.98 48.89
PLA:PCL/TCH −58.48 59.64 105.77 151.93 53.69
PLA:PCL/HNT-ASP/TCH −61.43 59.17 102.77 149.07 43.60
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Figure 7. DSC thermograms for selected PLA:PCL material samples.
PLA:PCL/HNT-ASP/TCH fibre mats possess the crystallisation temperature (Tc)
about 103 ◦C as opposed to 106◦C for PLA:PCL/TCH and 84 ◦C for PLA in PLA:PCL
counterparts. This result suggests that low-molecular-weight TCH enables to hinder the
cold crystallisation process of PLA in an anti-nucleating agent role as opposed to HNT-ASP.
On the other hand, loaded IMC results in an evident drop in Tm in contrast with a slight
decline in Tc. This finding lies in a better interaction between PLA:PCL fibre mats when
compared with the use of TCH. The Tg of PLA within the blends is hardly detected as it
has overlapped the melting peak of PCL
4.4. TGA Analysis
TGA spectra of electrospun nanocomposite fibre mats loaded with IMC and TCH are
exhibited in Figure 8. The addition of TCH, IMC or HNT-ASP does not appear to induce a
significant alteration in thermal stability of PCL with a narrow degradation peak range
from 398 to 399 ◦C. When TCH, IMC and HNT-ASP/TCH are incorporated, it is evidently
demonstrated that a peak shift to higher temperatures takes place within nanocomposite
fibre mats, thus retarding the thermal degradation. The temperature associated with
the TGA peak, which is assigned to PLA at 334 ◦C within PLA:PCL fibre mats, shifts
to 345 ◦C when loaded with IMC and further increases up to 350 ◦C with the addition
of TCH and HNT-ASP/TCH, resulting in much better thermal stability. Furthermore,
the residual masses were increasingly recorded to be 0.36%, 0.68%, 2.4% and 15.6% for
PLA:PCL, PLA:PCL/IMC, PLA:PCL/TCH and PLA:PCL/HNT-ASP/TCH fibre mats,
respectively. In particular, the higher residue mass of PLA:PCL/TCH when compared
with that of PLA:PCL/IMC can be ascribed to different molecular structures of TCH
(i.e., C22H25ClN2O8) with a larger number of carbon atoms relative to that of IMC (i.e.,
C19H16ClNO4).
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Figure 8. (a) TGA curves and (b) derivative thermogravimetric (DTGA) curves for typical PLA: PCL blend fibre mats.
4.5. FTIR Evaluation
Figure 9 depicts the FTIR spectra of PLA:PCL fibre mats loaded with or without TCH
and IMC for comparison in terms of their chemical bonding effect. The spectra of TCH
within PLA:PCL fibre mats and corresponding nanocomposite fibre mats do not appear
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to be easily assigned to the band shift. Nonetheless, corresponding TCH bands recorded
at 1614 and 1581 cm−1 within nanocomposite fibre mats are assigned to C=O stretchings
at ring A and ring C, respectively [38], signifying the successful encapsulation of TCH.
In a similar manner, effective encapsulation of IMC is also manifested, as evidenced by
the existing bond taking place at 1560 cm−1 associated with the ionisation of carboxyl
groups [39] according to the FTIR spectra of PLA:PCL/IMC fibre mats.
Figure 9. FTIR spectra for typical PLA:PCL based fibre mats showing drug effect on FTIR peaks.
4.6. In Vitro Drug Release
Drug particles within PLA:PCL fibre mats tend to remain on the fibre surfaces owing
to the fast solvent evaporation arising from the corresponding blend solution in electro-
spinning along with high ionic interactions [40]. As such, it is quite convincing that a
considerable burst release may happen at the initial drug-release stage. As a result of
weak interaction, the burst release becomes more pronounced on the condition that it is
incompatible between the drug and PLA:PCL solution. In comparison, the release rate
of hydrophilic drug TCH, when interacting with hydrophobic PLA:PCL blends, becomes
faster than that of hydrophobic drug IMC. As seen from Figure 10, drug release intends to
be quite rapid during the first 5 h, which is especially the case when using TCH (i.e., 42%
for PLA:PCL/TCH vs. 30% for PLA:PCL/IMC). This phenomenon is attributed to better
interaction and more active compatibility taking place between IMC and PLA:PCL fibre
mats, as opposed to the use of TCH. It is worth noting that chemical interaction between the
drug and its carrier may impede drug crystallisation within its carrier leading to a sustained
drug-release condition in a crystalline state [41]. The addition of 1 wt%/v HNT-ASP into
PLA:PCL blends can reduce initial burst release to 30% after 5 h as opposed to initial 42%
for PLA: PCL blends alone. In the meantime, a similar release trend was observed over the
steady release period from 50 to 250 h, indicating a robust drug release control over both
short and long evaluation periods, which appears to arise from the embedded HNT-ASP.
It is well known that HNTs possess negative charges on the outer surfaces while positive
charges on their inner surfaces [42]. Such distinct charges on HNT-ASP may give rise to the
electrostatic interaction identified between TCH and outer surfaces, as well as the lumen
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structures of HNT-ASP. Accordingly, the drug release rate of TCH can be reduced when
PLA:PCL/HNT-ASP nanocomposite fibre mats act as a drug carrier.
Figure 10. Drug release profiles for PLA:PCL fibre mats incorporated with IMC, TCH and HNT-
ASP/TCH.
4.7. Release Kinetics
The mechanism of drug release kinetics is vital to investigate the efficacy of drug
release with the carriers. Consequently, our drug release data obtained were fitted with
five mathematical models whose equations and corresponding parameters are explicitly
listed in Table 2. The conventional first-order model reveals that drug release rate can
completely depend on drug concentration and its carrier feature. Whereas, Ritger–Pappas
model demonstrates a particular drug release mechanism following a Fickian transport
phenomenon [26] according to n values in a dominant diffusion process. On the other hand,
Zeng model [20] reveals that drug release may be significantly influenced by the diffusion
process and close interaction between TCH and IMC drugs and PLA:PCL blend fibre mats
as an effective carrier. In particular, IMC has relatively low free energy variation between
free and bound states, namely ∆G shown in Table 2.It is found that ∆G = −2.1 × 10−21 for
IMC when compared with ∆G = −2.0 × 10−22 for TCH. PLA:PCL fibre mats are supposed
to decrease the release rate of hydrophobic IMC though it may not work for hydrophilic
TCH owing to their enhanced interaction. Additionally, the decrease in Koff values of IMC
presented in Table 2 implies a strong drug-carrier interaction when compared with Koff of
TCH ranging from 0.0033 to 0.0025 h−1.
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Table 2. Drug release parameters determined by fitting drug release data to five different mathematical models for drug
release kinetics.
Mathematical
Model Zero-Order First-Order Higuchi Ritger–Peppas Zeng
Equation Mt/M∞ = K0t Mt/M∞ = 1 − e−K1t Mt/M∞= KH t1/2 Mt/M∞ = KRtn **








Kon = 0.0049 h−1
Koff = 0.0025 h−1
Ks = 1.006 h−1












Kon = 0.0034 h−1
Koff = 0.0033 h–1
Ks = 1.160 h−1













Kon = 0.0012 h−1
Koff = 0.00068 h−1
Ks = 1.025 h−1
* ∆G = -2.2×10−21J
R2 = 0.986
** Mt/M∞ = (Koff/(Kon + Koff))(1 − e−KSt) + (Kon/(Kon + Koff))(1 − e−Kofft). * ∆G = −kBT ln(Kon/Koff) where kB is the Boltzmann’s constant
and T is the absolute temperature (300 K).
It is worth noting that with the incorporation of HNT-ASP into PLA:PCL fibre
mats, very minor alteration is evidently observed in KS though ∆G could decrease from
−2.0 × 10−22 to −2.2 × 10−21 J. This finding confirms that embedded HNT-ASP may de-
crease the drug release rate of TCH, and further overcome the fast release issue induced by
the poor interaction between loaded TCH and PLA:PCL fibre mats. Generally speaking,
the close interaction between TCH molecules and HNT-ASP enables to yield hydrogen
bonds with silanol groups mounted on HNT-ASP. Since our proposed models do not take
erosion/biodegradation and dimensional alteration of drug carriers into consideration,
TCH release data are hard to be completely fitted with those available models. On the
flip side, the fitting results based on Zeng model is seemingly in overall good agreement
with those obtained through experimental data because this model detected the effect
of interaction between both drugs (i.e., TCH and IMC) and the carrier (i.e., PLA: PCL
nanofibres) on the release rate.
4.8. Mass Loss of Fibre Mats
The biodegradability of PLA:PCL fibre mats in terms of mass loss is displayed in
Figure 11. After the degradation period from the first 3 to 72 h in PBS, it is well noted
that the weights of both PLA:PCL/TCH and PLA:PCL/IMC fibre mats have very trivial
variations. The difference of mass has been identified between them to just commence after
168 h. It is worth mentioning that mass loss tends to increase over the degradation time up
to 336 h by reaching the levels of 2.9% and 2.5% for PLA:PCL/TCH and PLA:PCL/IMC
fibre mats, respectively. Overall, PLA:PCL/HNT-ASP/TCH nanocomposite fibre mats
consistently gain the highest mass losses in all degradation time, as exemplified by 3.44%
at 336 h. The small mass loss may be ascribed to PCL within the blends, thus hindering the
water penetration inside the nanofibres. Additionally, water absorption has been found to
take place slowly since PCL behaves with hydrophobic and semi-crystalline characteristics.
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Figure 11. Mass loss of electrospun PLA:PCL fibre mats during both short and long degradation
periods.
In spite of smaller fibre diameters of PLA:PCL/TCH fibre mats, their degradation
seems to be relatively high as compared with those of PLA:PCL/IMC counterparts. When
hydrophilic drug TCH is released from fibre mats, it may accelerate the degradation
process of hydrophobic nanofibres in a more rapid manner due to its increased wettability,
as opposed to that of hydrophobic IMC drug. Moreover, HNTs have been detected to
improve the PBS absorption and also increase the porosity at the nanofiber surfaces for
PLA:PCL/HNT-ASP/TCH nanocomposite mats. Such a phenomenon presents the strong
evidence for the good incorporation of TCH drug molecules onto HNT-ASP in order to
reduce the drug release rate. However, such nanocomposite fibre mats may undergo
relatively high degradability.
5. Conclusions
It was found that the addition of TCH appears to increase the electrical conductivity of
PLA:PCL solution, thus considerably decreasing nanofiber diameters. However, nanofibre
diameters are shown to be further altered insignificantly when loaded with IMC. Loaded
TCH and IMC drugs help to decrease the degree of crystallinity, the Tg and Tm of PCL
within PLA:PCL fibre mats. FTIR spectra confirm the successful encapsulation of IMC and
TCH into PLA:PCL fibre mats and corresponding nanocomposites. Thermal degradation
of PLA may be delayed with the addition of these two drugs, as well as HNT-ASP/TCH in
nanocomposite fibre mats despite the little variation to PCL. When hydrophilic drug TCH
is loaded into HNT-ASP and hydrophobic PLA:PCL blends, it decreases the drug release
and overcomes the weak interaction between TCH and PLA:PCL blends. Such a typical
characteristic is evidenced by excellent agreement achieved between Ritger–Peppas model
and Zeng model and experimental data in order to clearly understand the mechanism of
drug release kinetics. These models might not completely fit drug release data because
they do not consider the erosion/biodegradation and dimensional alteration of the carriers.
The mass loss in relation to the degradation effect signifies good TCH-embedding effect
onto HNT-ASP leading to the reduction in drug release rate.
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